**Laboratory Test Report**

**\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

**Patient: SSN:**

**DOB:** unknown **Ordering Site:**

**Collection Date/Time:** **Ordering Physician:** unknown

**Site Accession No.**: PALO 17 2526 **PHRL Accession No.:** P15-0133

**\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

**Received Date/Time:** 12/22/14 13:15 **Sample Type:** plasma

**Test Date:** 12/22/14 **Report Date/Time:** 12/29/14 09:07

**Test Performed:** HIV-1 PR/RT Resistance Genotypea **Reference Range:** susceptible

**Resultsb:**

|  |  |
| --- | --- |
| **Protease (PR) Inhibitor Resistance Interpretationb** | |
| **atazanavir/r (ATV/r) -- Reyataz®** | Susceptible |
| **darunavir/r (DRV/r) -- Prezista®** | Susceptible |
| **fosamprenavir/r (FPV/r) -- Lexiva®** | Susceptible |
| **indinavir/r (IDV/r) -- Crixivan®** | Susceptible |
| **lopinavir/r (LPV/r) -- Kaletra®** | Susceptible |
| **nelfinavir (NFV) -- Viracept®** | Susceptible |
| **tipranavir/r (TPV/r) -- Aptivus®** | Susceptible |

|  |  |
| --- | --- |
| PR HIV Subtype | B |
| PR Codons Analyzed | 1-99 |
| PR Major Resistance Mutations Detected: | none |
| PR Accessory Resistance Mutations Detected: | none |
| Other Amino Acid Changes from Reference Sequence: | K20I, M26L |

**Patient: SSN:**

**Site Accession No.**: PALO 17 2526 **PHRL Accession No.:** P15-0133

|  |  |
| --- | --- |
| **Nucleos(t)ide Reverse Transcriptase (NRTI) Resistance Interpretationb** | |
| **abacavir (ABC) -- Ziagen®** | Low-Level Resistance |
| **zidovudine (AZT) -- Retrovir®** | High-Level Resistance |
| **emtricitabine (FTC) -- Emtriva®** | Susceptible |
| **lamivudine (3TC) -- Epivir®** | Susceptible |
| **tenofovir (TDF) -- Viread®** | Low-Level Resistance |

|  |  |
| --- | --- |
| **Non-nucleoside Reverse Transcriptase (NNRTI) Resistance Interpretationb** | |
| **efavirenz (EFV) -- Sustiva®** | High-Level Resistance |
| **etravirine (ETR) -- Intelence®** | Susceptible |
| **nevirapine (NVP) -- Viramune®** | High-Level Resistance |
| **rilpivirine (RPV) -- Edurant®** | Susceptible |

|  |  |
| --- | --- |
| RT HIV Subtype | B |
| RT Codons Analyzed | 1-252 |
| NRTI Resistance Mutations Detected: | K70R, T215Y |
| NNRTI Resistance Mutations Detected: | K103N |
| Other Amino Acid Changes from Reference Sequence: | None |

**Comments:** none

**\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

aThe test uses RT-PCR and population-based sequencing to determine the consensus nucleotide and resulting amino acid sequence of the HIV-1 protease (PR) and reverse transcriptase (RT) genes (Winters et al., J. Clin Invest 102(10):1769-1775, 1998). This test was developed and its performance characteristics determined by PHRL. The U.S. FDA has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

bClassification of resistance-associated mutations and drug resistance interpretations provided by the Stanford HIV Resistance Database version 8.3 (hivdb.stanford.edu). “/r” indicates boosted with ritonavir.